This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Walgreens Tumbles on Costly Global Deal (Update 1)

Stocks in this article: WAG ESRX CVS RAD KKR

The deal has benefits, such as creating new growth opportunities for Walgreens and its shareholders. "We applaud Walgreen management for no longer sitting on its hands from a strategic perspective given the ongoing Express Scripts impasse," wrote UBS analyst Jason DeRise in a Tuesday note to clients.

"Our sense is that investors will now begin to refocus on Walgreen as more of a growth investment opportunity as opposed to trading opportunity around a potential resolution (or lack thereof) to the ESRX dispute."

Separately, Walgreens reported fiscal third quarter earnings per share of 62 cents, meeting street estimates; however, a sales fell 3.4% year-over-year to $17.8 billion, slightly missing estimates. Last month, Nottingham, England -based Alliance Boots reported a 12% increase in annual profit, on growth at its wholesale pharmaceuticals business

In a sense, the deal marks a second attempt to buy Alliance Boots and turn a profit. In 2007, KKR and Alliance Boots Chairman Stefano Pessina took the company private in $12 billion pound buyout that was the largest private equity deal at the time. Since then, KKR says that Alliance Boots profits have surged 88%.

As part of 45% stake acquisition by Walgreen, KKR will receive $2 billion in cash and stock for roughly half of its Alliance Boots stake after it made a $2.45 billion investment in 2007. The private equity giant will also gain a seat on Walgreen's board.

"We are looking forward to working with Alliance Boots to leverage our combined strengths and provide an even broader range of innovative, cost-effective products and services to patients and customers across the healthcare landscape," said Walgreens chief executive Gregory Wasson, of Tuesday's stake acquisition.

"Together we will be ideally positioned to expand our customer offerings in our existing markets and become the health and wellbeing partner of choice in emerging markets."

That strategy counters other long-speculated options for Walgreens, including a takeover of debt-laden pharmacy and drug store giant Rite Aid (RAD - Get Report).

In November, Susquehanna Financial Group analyst Joseph Stauff wrote in a note to clients that Rite Aid could be a target of Walgreen, the largest U.S. drugstore chain. With Rite Aid, Walgreen would further bolster its near 30% market share, distancing it from CVS Caremark (CVS - Get Report), the industry second, noted Stauff.

In March, Credit Suisse analyst Edward Kelly said that a Rite Aid acquisition would help Walgreen push against drugstore competition by pharmacy benefits managers like CVS Caremark and Express Scripts, which completed a $29 billion 2011 acquisition of Medco Health Solutions (MHS).

Tuesday's deal counters those expectations and Walgreens previous M&A history, as it shifts its strategy internationally. In 2010, Walgreen spent $1.1 billion to buy New York-based drug-store chain Duane Reade from private equity firm Oak Hill Capital and was a bidder for Longs Drug Stores, another U.S. chain that was eventually bought by CVS Caremark.

For more on investing in drug stores and pharmacy giants see why Rite Aid's earnings overtake deal hopes and why Express Scripts could be sandbagging synergies.

-- Written by Antoine Gara in New York

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs